Ruckert Arne, Hoffman Steven J, Bishop Julia, Van Katwyk Susan Rogers, Fafard Patrick, Poirier Mathieu J P
Global Strategy Lab, Dahdaleh Institute for Global Health Research, York University, Toronto, Ontario, Canada.
School of Global Health, Faculty of Health, York University, Toronto, Ontario, Canada.
PLOS Glob Public Health. 2025 Jan 3;5(1):e0004039. doi: 10.1371/journal.pgph.0004039. eCollection 2025.
Effective global action against antimicrobial resistance (AMR) relies on the successful synthesis and translation of rigorous scientific evidence into policy and practice. Despite a call in 2019 by the Interagency Coordination Group on AMR to establish a policy-science interface, and the reaffirmation to establish a scientific panel in the 2024 Political Declaration on Antimicrobial Resistance, no authoritative entity currently exists that synthesizes the scientific evidence on AMR and outlines policy options based on the best scientific insight. A Scientific Panel on Evidence for Action against AMR (SPEA) could address this gap, as well as contribute to additional governance gaps in the space of AMR, by facilitating better global coordination and cooperation; establishing real-time evidence to guide policy actions; and monitoring progress towards any globally agreed upon AMR goals and targets. In this essay, we argue that SPEA has the potential to fulfill several governance functions, and we explore two design options for such a scientific panel to promote equitable and evidence-informed policy implementation. We first reflect on how the successes and failures of the Intergovernmental Panel on Climate Change (IPCC) should inform the SPEA. Building on these lessons, we then highlight the key functions of the SPEA, before proposing two models for how it could function in the context of the existing global governance of AMR. Finally, we reflect on the challenges inherent to each proposed governance model. The recent reaffirmation by the United Nations General Assembly to establish a scientific panel in the area of AMR represents a critical opportunity to enhance global AMR governance, promote evidence-based policy implementation, and foster international cooperation in combatting AMR.
全球有效应对抗菌药物耐药性（AMR）的行动依赖于将严谨的科学证据成功整合并转化为政策与实践。尽管抗菌药物耐药性问题跨部门协调小组在2019年呼吁建立政策与科学的接口，且《2024年抗菌药物耐药性问题政治宣言》重申要设立一个科学小组，但目前尚无权威机构来整合有关抗菌药物耐药性的科学证据，并依据最佳科学见解概述政策选项。一个抗菌药物耐药性行动证据科学小组（SPEA）可以填补这一空白，还能通过促进更好的全球协调与合作、建立实时证据以指导政策行动，以及监测在实现任何全球商定的抗菌药物耐药性目标方面的进展，来弥补抗菌药物耐药性领域的其他治理差距。在本文中，我们认为抗菌药物耐药性行动证据科学小组有潜力履行多项治理职能，并探讨了这样一个科学小组的两种设计方案，以促进公平且基于证据的政策实施。我们首先思考政府间气候变化专门委员会（IPCC）的成败应如何为抗菌药物耐药性行动证据科学小组提供借鉴。基于这些经验教训，我们接着强调抗菌药物耐药性行动证据科学小组的关键职能，然后提出该小组在现有抗菌药物耐药性全球治理背景下可能发挥作用的两种模式。最后，我们思考了每种提议的治理模式所固有的挑战。联合国大会最近重申要在抗菌药物耐药性领域设立一个科学小组，这是加强全球抗菌药物耐药性治理、促进基于证据的政策实施以及推动抗击抗菌药物耐药性国际合作的关键契机。
